window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

gene therapy development

  • Biotech,Mergers & Acquisitions,Opthalmology,Research & Development,Technology and platforms

    Axol Bioscience acquires Newcells ophthalmology business to expand retinal organoid portfolio

    Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, [...]

    February 19, 2026
  • Cell & Gene Therapy,Genetic Diseases,Research & Development,RNA Therapeutics

    SynGenSys launches Liver.SET library for liver-specific gene expression in in vivo therapies

    SynGenSys has launched Liver.SET, a library of liver-specific synthetic promoters [...]

    February 5, 2026
  • Cell & Gene Therapy,Partnerships & Funding,Technology and platforms

    Broken String and BioLizard partner on AI tool to improve gene editing safety

    Eurostars-3 grant supports development of SafeGuide to reduce time and [...]

    July 14, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top